Literature DB >> 3121242

Quality control limits for microdilution susceptibility tests with aztreonam, imipenem, ceftriaxone, ceftazidime, ceftizoxime, cefuroxime, and cefonicid.

A L Barry1, T L Gavan, R N Jones, L W Ayers, P C Fuchs, E H Gerlach, C Thornsberry.   

Abstract

A six-laboratory collaborative study was performed in order to define quality control limits for microdilution tests with seven new beta-lactams (aztreonam, imipenem, ceftriaxone, ceftazidime, ceftizoxime, cefuroxime, and cefonicid). Four standard control strains were tested and the expected MIC limits for each of the appropriate drug-microorganism combinations were defined.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3121242     DOI： 10.1016/0732-8893(87)90076-9

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN： 0732-8893            Impact factor:   2.803


  12 in total

1.  False resistance to imipenem with a microdilution susceptibility testing system.

Authors:  E J O'Rourke; K G Lambert; K C Parsonnet; A B Macone; D A Goldmann
Journal:  J Clin Microbiol       Date:  1991-04       Impact factor: 5.948

2.  Quality control parameters and interpretive criteria for in vitro susceptibility tests with the macrolide azithromycin. Collaborative Antimicrobial Susceptibility Testing Group.

Authors:  A L Barry; C Thornsberry; T L Gavan
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-06       Impact factor: 3.267

3.  Criteria for disk susceptibility tests and quality control guidelines for the cefoperazone-sulbactam combination.

Authors:  A L Barry; R N Jones
Journal:  J Clin Microbiol       Date:  1988-01       Impact factor: 5.948

4.  Susceptibility testing of carumonam: interpretive criteria for 30-microgram disk tests and quality control guidelines for disk diffusion and broth microdilution methods.

Authors:  R N Jones; A L Barry
Journal:  J Clin Microbiol       Date:  1987-11       Impact factor: 5.948

5.  In vitro activity of FCE 22101, imipenem, and ceftazidime against over 6,000 bacterial isolates and MIC quality control limits of FCE 22101.

Authors:  A L Barry; K E Aldridge; S D Allen; P C Fuchs; E H Gerlach; R N Jones; M A Pfaller
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-12       Impact factor: 3.267

6.  Interpretive criteria and quality control parameters for testing of susceptibilities of Haemophilus influenzae and Streptococcus pneumoniae to trimethoprim and trimethoprim-sulfamethoxazole. The Antimicrobial Susceptibility Testing OC Group.

Authors:  P C Fuchs; A L Barry; S D Brown
Journal:  J Clin Microbiol       Date:  1997-01       Impact factor: 5.948

7.  Disk diffusion susceptibility testing and broth microdilution quality control guidelines for BMY-28100, a new orally administered cephalosporin.

Authors:  R N Jones; A L Barry
Journal:  J Clin Microbiol       Date:  1987-11       Impact factor: 5.948

8.  Optimal dilution susceptibility testing conditions, recommendations for MIC interpretation, and quality control guidelines for the ampicillin-sulbactam combination.

Authors:  R N Jones; A L Barry
Journal:  J Clin Microbiol       Date:  1987-10       Impact factor: 5.948

9.  Standardization of disk diffusion and agar dilution susceptibility tests for Neisseria gonorrhoeae: interpretive criteria and quality control guidelines for ceftriaxone, penicillin, spectinomycin, and tetracycline.

Authors:  R N Jones; T L Gavan; C Thornsberry; P C Fuchs; E H Gerlach; J S Knapp; P Murray; J A Washington
Journal:  J Clin Microbiol       Date:  1989-12       Impact factor: 5.948

10.  Ceftibuten (7432-S, SCH 39720): comparative antimicrobial activity against 4735 clinical isolates, beta-lactamase stability and broth microdilution quality control guidelines.

Authors:  R N Jones; A L Barry
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-12       Impact factor: 3.267
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.